Abstract
Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.
Original language | English (US) |
---|---|
Pages (from-to) | 206-218 |
Number of pages | 13 |
Journal | Prostate Cancer and Prostatic Diseases |
Volume | 14 |
Issue number | 3 |
DOIs | |
State | Published - Sep 2011 |
Fingerprint
Keywords
- castrate-resistant prostate cancer
- clinical trials
- drug development
- novel therapies
ASJC Scopus subject areas
- Oncology
- Urology
- Cancer Research
Cite this
Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. / Antonarakis, Emmanuel; Armstrong, A. J.
In: Prostate Cancer and Prostatic Diseases, Vol. 14, No. 3, 09.2011, p. 206-218.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer
AU - Antonarakis, Emmanuel
AU - Armstrong, A. J.
PY - 2011/9
Y1 - 2011/9
N2 - Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.
AB - Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.
KW - castrate-resistant prostate cancer
KW - clinical trials
KW - drug development
KW - novel therapies
UR - http://www.scopus.com/inward/record.url?scp=80054749674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054749674&partnerID=8YFLogxK
U2 - 10.1038/pcan.2011.24
DO - 10.1038/pcan.2011.24
M3 - Article
C2 - 21577233
AN - SCOPUS:80054749674
VL - 14
SP - 206
EP - 218
JO - Prostate Cancer and Prostatic Diseases
JF - Prostate Cancer and Prostatic Diseases
SN - 1365-7852
IS - 3
ER -